Frakefamide

Source: Wikipedia, the free encyclopedia.
Frakefamide
Clinical data
Other namesL-Tyrosyl-D-alanyl-4-fluoro-L-phenylalanyl-L-phenylalaninamide
ATC code
  • None
Identifiers
  • (2S)-2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-N-[(1S)-1-carbamoyl-2-phenylethyl]-3-(4-fluorophenyl)propanamide
JSmol)
  • C[C@H](C(=O)N[C@@H](CC1=CC=C(C=C1)F)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
  • InChI=1S/C30H34FN5O5/c1-18(34-29(40)24(32)15-20-9-13-23(37)14-10-20)28(39)36-26(17-21-7-11-22(31)12-8-21)30(41)35-25(27(33)38)16-19-5-3-2-4-6-19/h2-14,18,24-26,37H,15-17,32H2,1H3,(H2,33,38)(H,34,40)(H,35,41)(H,36,39)/t18-,24+,25+,26+/m1/s1
  • Key:GTPHQORJKFJIRB-JTQLPTLWSA-N

Frakefamide (

Shire but was shelved after phase II clinical trials.[4][5]

See also

References

  1. ^
    S2CID 23249323
    .
  2. ISBN 978-0-444-53273-2
    . Retrieved 27 April 2012.
  3. S2CID 40297091
    .
  4. ISBN 978-0-12-386537-3
    . Retrieved 27 April 2012.
  5. ISBN 978-0-8247-8865-0
    . Retrieved 27 April 2012.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Frakefamide&oldid=1188247967"